<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR941202-1-00002</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> DATES: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Submit comments by February 15, 1995. Comments received after this date will be considered if it is  <!-- PJG 0012 frnewline --> practical to do so, but assurance of consideration cannot be given except as  <!-- PJG 0012 frnewline --> to comments received on or before this date. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4702 -->  <!-- PJG ITAG l=50 g=1 f=1 --> NUCLEAR REGULATORY COMMISSION  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 -->  <CFRNO>10 CFR Part 35 </CFRNO> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=41 g=1 f=1 -->  <RINDOCK>[Docket No. PRM&hyph;35&hyph;12] </RINDOCK> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 --> Tri-Med Specialties, Inc.; Filing of Petition for Rulemaking  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Nuclear Regulatory Commission. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Notice of receipt of petition for rulemaking. <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  The Nuclear Regulatory Commission (NRC) is publishing for public comment a notice of receipt of a petition for rulemaking, dated August 23, 1994, that was filed with the Commission by Tri-Med Specialties, Inc. The  <!-- PJG 0012 frnewline --> petition was assigned Docket No. PRM&hyph;35&hyph;12 on October 6, 1994. The petitioner  <!-- PJG 0012 frnewline --> requests that the Commission amend its regulations to permit licensed  <!-- PJG 0012 frnewline --> pharmaceutical manufacturers to commercially distribute, under general  <!-- PJG 0012 frnewline --> licensing and/or exemption, capsules containing one micro-curie of carbon-14  <!-- PJG 0012 frnewline --> (C14) for administration to humans for in vivo diagnostic testing. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> DATES: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Submit comments by February 15, 1995. Comments received after this date will be considered if it is  <!-- PJG 0012 frnewline --> practical to do so, but assurance of consideration cannot be given except as  <!-- PJG 0012 frnewline --> to comments received on or before this date. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Submit comments to the Secretary, U.S. Nuclear Regulatory  <!-- PJG 0012 frnewline --> Commission, Attention: Docketing and Service Branch, Washington DC 20555. For  <!-- PJG 0012 frnewline --> a copy of the petition, write to the Rules Review Section, Rules Review and  <!-- PJG 0012 frnewline --> Directives Branch, Division of Freedom of Information and Publications  <!-- PJG 0012 frnewline --> Services, Office of Administration, U.S. Nuclear Regulatory Commission,  <!-- PJG 0012 frnewline --> Washington, DC 20555. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </ADDRESS> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Michael T. Lesar, Chief, Rules Review  <!-- PJG 0012 frnewline --> Section, Rules Review and Directives Branch, Division of Freedom of  <!-- PJG 0012 frnewline --> Information and Publications Services, Office of Administration, U.S. Nuclear  <!-- PJG 0012 frnewline --> Regulatory Commission, Washington, DC 20555. Telephone: 301&hyph;415&hyph;7163 or toll  <!-- PJG 0012 frnewline --> free: 1&hyph;800&hyph;368&hyph;5642.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=84 g=1 f=2 --> SUPPLEMENTARY INFORMATION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 -->   <!-- PJG 0012 frnewline --> Petitioner  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Tri-Med Specialties, Inc., headquartered in Overland Park, Kansas,  <!-- PJG 0012 frnewline --> maintains a licensed pharmaceutical manufacturing site in Charlottesville,  <!-- PJG 0012 frnewline --> Virginia. The petitioner also is licensed by the NRC ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=6 f=1 --> # <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 45&hyph;25215&hyph;01) to  <!-- PJG 0012 frnewline --> perform research using C14. This research involves manufacture of capsules  <!-- PJG 0012 frnewline --> containing 1 micro-curie ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=6 f=1 --> m <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Ci) of C14-urea and production of diagnostic breath  <!-- PJG 0012 frnewline --> test kits. The test kits are currently transferred only to facilities  <!-- PJG 0012 frnewline --> licensed by the Food and Drug Administration (FDA) (IND <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=6 f=1 --> # <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 42294) and the NRC.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Petitioner's Request  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Tri-Med Specialties requests that the NRC amend its regulations to allow  <!-- PJG 0012 frnewline --> for the general licensing and/or exemption for the commercial distribution by  <!-- PJG 0012 frnewline --> licensed pharmaceutical manufacturers of a capsule containing 1  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=6 f=1 --> m <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Ci of C14-urea for in vivo diagnostic testing. The petitioner states that the capsules  <!-- PJG 0012 frnewline --> would be used to test for the presence of Helicobacter pylori, a bacterium  <!-- PJG 0012 frnewline --> that causes peptic ulcers in the stomach. According to the petitioner, the  <!-- PJG 0012 frnewline --> capsules would be distributed separately or as part of a diagnostic kit that  <!-- PJG 0012 frnewline --> contains supplies to perform the test. The petitioner suggests the maximum  <!-- PJG 0012 frnewline --> number of capsules allowed in inventory at an unlicensed facility at any time  <!-- PJG 0012 frnewline --> be 150 (150  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=6 f=1 --> m <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Ci).  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Grounds for Request  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The petitioner states that recent medical research has found peptic  <!-- PJG 0012 frnewline --> ulcers are commonly caused by the H.pylori bacterium that lives in the stomach  <!-- PJG 0012 frnewline --> of most ulcer sufferers. According to the petitioner, in the past, doctors  <!-- PJG 0012 frnewline --> used the endoscopy and biopsy procedure to detect the stomach ulcers. This  <!-- PJG 0012 frnewline --> procedure was uncomfortable and expensive at a cost of $1000. The petitioner  <!-- PJG 0012 frnewline --> states that by using a C14-urea tracer, H.pylori can be detected noninvasively  <!-- PJG 0012 frnewline --> by having the patient swallow a capsule with 30 milliliters of water. C14-urea is broken down by H.pylori to form labeled CO <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=2 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> , which is expired in the  <!-- PJG 0012 frnewline --> breath. The petitioner asserts that the C14-urea test could be performed by  <!-- PJG 0012 frnewline --> most doctors for less than $100 cost to the patient.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Public Impact  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The petitioner notes that the risks from the C14-urea test would be very  <!-- PJG 0012 frnewline --> low because the 1  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=6 f=1 --> m <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Ci of C14-urea consumed by the patient is rapidly excreted  <!-- PJG 0012 frnewline --> as urea in the urine or CO <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=2 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  in the breath. The petitioner states that the  <!-- PJG 0012 frnewline --> radiation dose received by the patient would be 0.3 millirem (an amount equal  <!-- PJG 0012 frnewline --> to background radiation received in 24 hours). The risk for persons  <!-- PJG 0012 frnewline --> administering the test would be immeasurably low and risk to the public would  <!-- PJG 0012 frnewline --> be close to zero.  <!-- PJG 0012 frnewline --> The petitioner indicates that the Commission's regulations currently  <!-- PJG 0012 frnewline --> contain provisions for a general license whereby physicians and veterinarians  <!-- PJG 0012 frnewline --> can receive, use, and dispose of byproduct material for in vitro clinical or  <!-- PJG 0012 frnewline --> laboratory testing without applying for a specific license. According to the  <!-- PJG 0012 frnewline --> petitioner, these recipients are required only to be registered with the NRC.  <!-- PJG 0012 frnewline --> The petitioner further asserts that the Commission's regulations permit other  <!-- PJG 0012 frnewline --> general licenses that have a greater likelihood of affecting the public than  <!-- PJG 0012 frnewline --> the proposed C14-urea test.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Benefits of the Test  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The petitioner states that under the current regulations, the test is  <!-- PJG 0012 frnewline --> 95-percent accurate and quite inexpensive because of its simplicity. The test  <!-- PJG 0012 frnewline --> would permit doctors to determine easily whether or not ulcer patients have  <!-- PJG 0012 frnewline --> been cured of their infection. The benefits to the public, according to the  <!-- PJG 0012 frnewline --> petitioner, would be a curative therapy for ulcers that can be made available  <!-- PJG 0012 frnewline --> to all people, thus saving the United States an estimated $500 million per  <!-- PJG 0012 frnewline --> annum over conventional therapy.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Conclusion  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The petitioner states that the test may be supplied currently only to  <!-- PJG 0012 frnewline --> facilities licensed to receive C14. According to the petitioner, this  <!-- PJG 0012 frnewline --> requirement makes the test prohibitively expensive for the great majority of  <!-- PJG 0012 frnewline --> doctors. The petitioner states that the test is currently being studied at  <!-- PJG 0012 frnewline --> four sites under a Notice of Claimed Investigational Exemption for a New Drug  <!-- PJG 0012 frnewline --> (IND) application accepted by the FDA and is also being used at other sites  <!-- PJG 0012 frnewline --> under approved research protocols. The petitioner states that all of these  <!-- PJG 0012 frnewline --> sites are using the test under the petitioner's IND and are also licensed by  <!-- PJG 0012 frnewline --> the NRC to administer C14 to patients for diagnostic testing. The petitioner  <!-- PJG 0012 frnewline --> states that more than 200 tests have been performed at these additional sites  <!-- PJG 0012 frnewline --> and that no adverse events from the tests performed as of this date have been  <!-- PJG 0012 frnewline --> reported. Therefore, the petitioner believes that licensed pharmaceutical  <!-- PJG 0012 frnewline --> manufacturers should be permitted to distribute the capsule containing 1  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=6 f=1 --> m <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Ci  <!-- PJG 0012 frnewline --> of C14-urea for in vivo diagnostic testing.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Additional Documents  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The petition includes additional justification and support for the  <!-- PJG 0012 frnewline --> requested amendment not included in this  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  notice. Members of  <!-- PJG 0012 frnewline --> the public interested in filing comments on PRM&hyph;35&hyph;12 can obtain a copy of the  <!-- PJG 0012 frnewline --> petition and supporting documentation by writing to the address noted above. <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated at Rockville, Maryland, this 28th day of November, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> For the Nuclear Regulatory Commission.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> John C. Hoyle  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Acting Secretary of the Commission. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;29654 Filed 12&hyph;1&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 7590&hyph;01&hyph;P <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            